Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Biosimilar Red Tape Elimination Act
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Inflation Reduction Act implementation. H.R.5526/S.1954 - Biosimilar Red Tape Elimination Act.
Biosimilar Red Tape Elimination Act
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Inflation Reduction Act implementation. H.R.5526/S.1954 - Biosimilar Red Tape Elimination Act.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
THE SPEAK FOUNDATION via THORN RUN PARTNERS
2026 · third_quarter · Q3
Rare disease and FDA issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE BIOSIMILARS FORUM via THORN RUN PARTNERS
2026 · third_quarter · Q3
Source: Senate LDA
Biosimilar Red Tape Elimination Act
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Inflation Reduction Act implementation. H.R.5526/S.1954 - Biosimilar Red Tape Elimination Act. H.R.9661/S.1414 - Expedited Access to Biosimilars Act.
Expedited Access to Biosimilars Act
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Inflation Reduction Act implementation. H.R.5526/S.1954 - Biosimilar Red Tape Elimination Act. H.R.9661/S.1414 - Expedited Access to Biosimilars Act.
Expedited Access to Biosimilars Act
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees. S.2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026. H.R.9661/S.1414 - Expedited Access to Biosimilars Act.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Inflation Reduction Act implementation. H.R.5526/S.1954 - Biosimilar Red Tape Elimination Act. H.R.9661/S.1414 - Expedited Access to Biosimilars Act.
Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees. S.2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026. H.R.9661/S.1414 - Expedited Access to Biosimilars Act.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Inflation Reduction Act implementation. H.R.5526/S.1954 - Biosimilar Red Tape Elimination Act. H.R.9661/S.1414 - Expedited Access to Biosimilars Act.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Inflation Reduction Act implementation. H.R.5526/S.1954 - Biosimilar Red Tape Elimination Act.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Inflation Reduction Act implementation. H.R.5526/S.1954 - Biosimilar Red Tape Elimination Act.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees. S.2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees. S.2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026. H.R.9661/S.1414 - Expedited Access to Biosimilars Act.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees. S.2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026.
Biosimilar Red Tape Elimination Act
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Inflation Reduction Act implementation. H.R.5526/S.1954 - Biosimilar Red Tape Elimination Act.
Biosimilar Red Tape Elimination Act
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Inflation Reduction Act implementation. H.R.5526/S.1954 - Biosimilar Red Tape Elimination Act.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Inflation Reduction Act implementation. H.R.5526/S.1954 - Biosimilar Red Tape Elimination Act.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Inflation Reduction Act implementation. H.R.5526/S.1954 - Biosimilar Red Tape Elimination Act.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees. S.2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees. S.2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees. S.2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act. Inflation Reduction Act implementation.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act. Inflation Reduction Act implementation.
Pharmacy Benefits Manager Accountability Act
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act. Inflation Reduction Act implementation.
Pharmacy Benefits Manager Accountability Act
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act.
Pharmacy Benefits Manager Accountability Act
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act. Inflation Reduction Act implementation.
Pharmacy Benefits Manager Accountability Act
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. H.R.2679 - Pharmacy Benefits Manager Accountability Act. S.2305 - Biosimilar Red Tape Elimination Act. Inflation Reduction Act implementation.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act. Inflation Reduction Act implementation.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act. Inflation Reduction Act implementation.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. H.R.2679 - Pharmacy Benefits Manager Accountability Act. S.2305 - Biosimilar Red Tape Elimination Act. Inflation Reduction Act implementation.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act. Inflation Reduction Act implementation.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act. Inflation Reduction Act implementation.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act.
Pharmacy Benefits Manager Accountability Act
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023.
Pharmacy Benefits Manager Accountability Act
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act.
Pharmacy Benefits Manager Accountability Act
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023.
Consolidated Appropriations Act, 2023
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. H.R.2617 - Consolidated Appropriations Act, 2023, as it relates to the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023. H.R.2815 - BIOSIM Act. H.R.2855 - Star Rating for Biosimilars Act. H.R.2869/S.1427 - Increasing Access to Biosimilars Act of 2021. H.R.5376 - Inflation Reduction Act of 2022
Drug pricing legislation. H.R.4502 - Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022. H.R.2815 - BIOSIM Act. H.R.2855 - Star Rating for Biosimilars Act. H.R.2869/S.1427 - Increasing Access to Biosimilars Act of 2021. H.R.5376 - Inflation Reduction Act of 2022. Efforts surrounding user fees. H.R.7006 - INSPECTIONS Act.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. H.R.2617 - Consolidated Appropriations Act, 2023, as it relates to the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023. H.R.2815 - BIOSIM Act. H.R.2855 - Star Rating for Biosimilars Act. H.R.2869/S.1427 - Increasing Access to Biosimilars Act of 2021. H.R.5376 - Inflation Reduction Act of 2022
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. H.R.2617 - Consolidated Appropriations Act, 2023, as it relates to the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023. H.R.2815 - BIOSIM Act. H.R.2855 - Star Rating for Biosimilars Act. H.R.2869/S.1427 - Increasing Access to Biosimilars Act of 2021. H.R.5376 - Inflation Reduction Act of 2022
Drug pricing legislation. H.R.4502 - Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022. H.R.2815 - BIOSIM Act. H.R.2855 - Star Rating for Biosimilars Act. H.R.2869/S.1427 - Increasing Access to Biosimilars Act of 2021. H.R.5376 - Inflation Reduction Act of 2022. Efforts surrounding user fees. H.R.7006 - INSPECTIONS Act.
Increasing Access to Biosimilars Act of 2021
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. H.R.2617 - Consolidated Appropriations Act, 2023, as it relates to the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023. H.R.2815 - BIOSIM Act. H.R.2855 - Star Rating for Biosimilars Act. H.R.2869/S.1427 - Increasing Access to Biosimilars Act of 2021. H.R.5376 - Inflation Reduction Act of 2022
Increasing Access to Biosimilars Act of 2021
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Drug pricing legislation. H.R.4502 - Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022. H.R.2815 - BIOSIM Act. H.R.2855 - Star Rating for Biosimilars Act. H.R.2869/S.1427 - Increasing Access to Biosimilars Act of 2021. H.R.5376 - Inflation Reduction Act of 2022. Efforts surrounding user fees. H.R.7006 - INSPECTIONS Act.
Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Drug pricing legislation. H.R.4502 - Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022. H.R.2815 - BIOSIM Act. H.R.2855 - Star Rating for Biosimilars Act. H.R.2869/S.1427 - Increasing Access to Biosimilars Act of 2021. H.R.5376 - Inflation Reduction Act of 2022. Efforts surrounding user fees. H.R.7006 - INSPECTIONS Act.
Drug pricing legislation. H.R.4502 - Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022. H.R.2815 - BIOSIM Act. H.R.2855 - Star Rating for Biosimilars Act. H.R.2869/S.1427 - Increasing Access to Biosimilars Act of 2021. H.R.5376 - Inflation Reduction Act of 2022. Efforts surrounding user fees. H.R.7006 - INSPECTIONS Act.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. H.R.2617 - Consolidated Appropriations Act, 2023, as it relates to the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023. H.R.2815 - BIOSIM Act. H.R.2855 - Star Rating for Biosimilars Act. H.R.2869/S.1427 - Increasing Access to Biosimilars Act of 2021. H.R.5376 - Inflation Reduction Act of 2022
Drug pricing legislation. H.R.4502 - Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022. H.R.2815 - BIOSIM Act. H.R.2855 - Star Rating for Biosimilars Act. H.R.2869/S.1427 - Increasing Access to Biosimilars Act of 2021. H.R.5376 - Inflation Reduction Act of 2022. Efforts surrounding user fees. H.R.7006 - INSPECTIONS Act.
Increasing Access to Biosimilars Act of 2021
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. H.R.2617 - Consolidated Appropriations Act, 2023, as it relates to the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023. H.R.2815 - BIOSIM Act. H.R.2855 - Star Rating for Biosimilars Act. H.R.2869/S.1427 - Increasing Access to Biosimilars Act of 2021. H.R.5376 - Inflation Reduction Act of 2022
Increasing Access to Biosimilars Act of 2021
Client: THE BIOSIMILARS FORUM · Firm: THORN RUN PARTNERS
Drug pricing legislation. H.R.4502 - Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022. H.R.2815 - BIOSIM Act. H.R.2855 - Star Rating for Biosimilars Act. H.R.2869/S.1427 - Increasing Access to Biosimilars Act of 2021. H.R.5376 - Inflation Reduction Act of 2022. Efforts surrounding user fees. H.R.7006 - INSPECTIONS Act.
Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees. S.2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026. H.R.9661/S.1414 - Expedited Access to Biosimilars Act.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Inflation Reduction Act implementation. H.R.5526/S.1954 - Biosimilar Red Tape Elimination Act. H.R.9661/S.1414 - Expedited Access to Biosimilars Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SECRETOME THERAPEUTICS via THORN RUN PARTNERS
2026 · third_quarter · Q3
Education related to neonatal stem cell research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DYSAUTONOMIA INTERNATIONAL via THORN RUN PARTNERS
2026 · third_quarter · Q3
Advocating for funding for public awareness, federal research, and provider education on POTS and similar forms of dysautonomia.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE SPEAK FOUNDATION via THORN RUN PARTNERS
2026 · second_quarter · Q2
Rare disease and FDA issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SECRETOME THERAPEUTICS via THORN RUN PARTNERS
2026 · second_quarter · Q2
Education related to neonatal stem cell research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KERBEROS CAPITAL FUND III LP via THORN RUN PARTNERS
2026 · second_quarter · 2T
International Tax Policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DYSAUTONOMIA INTERNATIONAL via THORN RUN PARTNERS
2026 · second_quarter · Q2
Advocating for funding for public awareness, federal research, and provider education on POTS and similar forms of dysautonomia.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE BIOSIMILARS FORUM via THORN RUN PARTNERS
2026 · second_quarter · Q2
Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees. S.2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Inflation Reduction Act implementation. H.R.5526/S.1954 - Biosimilar Red Tape Elimination Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
THE SPEAK FOUNDATION via THORN RUN PARTNERS
2026 · first_quarter · Q1
Rare disease and FDA issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE BIOSIMILARS FORUM via THORN RUN PARTNERS
2026 · first_quarter · Q1
Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees. S.2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Inflation Reduction Act implementation. H.R.5526/S.1954 - Biosimilar Red Tape Elimination Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SECRETOME THERAPEUTICS via THORN RUN PARTNERS
2026 · first_quarter · Q1
Education related to neonatal stem cell research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KERBEROS CAPITAL FUND III LP via THORN RUN PARTNERS
2026 · first_quarter · Q1
International Tax Policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DYSAUTONOMIA INTERNATIONAL via THORN RUN PARTNERS
2026 · first_quarter · Q1
Advocating for funding for public awareness, federal research, and provider education on POTS and similar forms of dysautonomia.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE SPEAK FOUNDATION via THORN RUN PARTNERS
2025 · fourth_quarter · Q4
Rare disease and FDA issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE BIOSIMILARS FORUM via THORN RUN PARTNERS
2025 · fourth_quarter · Q4
Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees. S.2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Inflation Reduction Act implementation. H.R.5526/S.1954 - Biosimilar Red Tape Elimination Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SECRETOME THERAPEUTICS via THORN RUN PARTNERS
2025 · fourth_quarter · Q4
Education related to neonatal stem cell research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DYSAUTONOMIA INTERNATIONAL via THORN RUN PARTNERS
2025 · fourth_quarter · Q4
Advocating for funding for public awareness, federal research, and provider education on POTS and similar forms of dysautonomia.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KERBEROS CAPITAL FUND III LP via THORN RUN PARTNERS
2025 · fourth_quarter · Q4
International Tax Policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE SPEAK FOUNDATION via THORN RUN PARTNERS
2025 · fourth_quarter · RR
Rare disease and FDA issues.
THE BIOSIMILARS FORUM via THORN RUN PARTNERS
2025 · third_quarter · Q3
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Inflation Reduction Act implementation. H.R.5526/S.1954 - Biosimilar Red Tape Elimination Act.
Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees. S.2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SECRETOME THERAPEUTICS via THORN RUN PARTNERS
2025 · third_quarter · Q3
Education related to neonatal stem cell research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KERBEROS CAPITAL FUND III LP via THORN RUN PARTNERS
2025 · third_quarter · Q3
International Tax Policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DYSAUTONOMIA INTERNATIONAL via THORN RUN PARTNERS
2025 · third_quarter · Q3
Advocating for funding for public awareness, federal research, and provider education on POTS and similar forms of dysautonomia.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SECRETOME THERAPEUTICS via THORN RUN PARTNERS
2025 · third_quarter · RR
Education related to neonatal stem cell research.
KERBEROS CAPITAL FUND III LP via THORN RUN PARTNERS
2025 · second_quarter · Q2
International Tax Policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE BIOSIMILARS FORUM via THORN RUN PARTNERS
2025 · second_quarter · Q2
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Inflation Reduction Act implementation.
Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees. S.2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MODERN MEDICAID ALLIANCE via THORN RUN PARTNERS
2025 · second_quarter · Q2
Protect the Medicaid program from funding cuts and policy changes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DYSAUTONOMIA INTERNATIONAL via THORN RUN PARTNERS
2025 · second_quarter · Q2
Advocating for funding for public awareness, federal research, and provider education on POTS and similar forms of dysautonomia.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KERBEROS CAPITAL FUND III LP via THORN RUN PARTNERS
2025 · second_quarter · RR
International Tax Policy.
DYSAUTONOMIA INTERNATIONAL via THORN RUN PARTNERS
2025 · second_quarter · RR
Advocating for funding for public awareness, federal research, and provider education on POTS and similar forms of dysautonomia.
THE BIOSIMILARS FORUM via THORN RUN PARTNERS
2025 · first_quarter · Q1
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Inflation Reduction Act implementation.
Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MODERN MEDICAID ALLIANCE via THORN RUN PARTNERS
2025 · first_quarter · Q1
Protect the Medicaid program from funding cuts and policy changes.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MODERN MEDICAID ALLIANCE via THORN RUN PARTNERS
2025 · first_quarter · RR
Protect the Medicaid program from funding cuts and policy changes.
THE BIOSIMILARS FORUM via THORN RUN PARTNERS
2024 · fourth_quarter · Q4
Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. H.R.2679 - Pharmacy Benefits Manager Accountability Act. S.2305 - Biosimilar Red Tape Elimination Act. Inflation Reduction Act implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE BIOSIMILARS FORUM via THORN RUN PARTNERS
2024 · third_quarter · Q3
Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act. Inflation Reduction Act implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE BIOSIMILARS FORUM via THORN RUN PARTNERS
2024 · second_quarter · Q2
Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act. Inflation Reduction Act implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE BIOSIMILARS FORUM via THORN RUN PARTNERS
2024 · first_quarter · Q1
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act.
Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE BIOSIMILARS FORUM via THORN RUN PARTNERS
2023 · fourth_quarter · Q4
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act.
Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE BIOSIMILARS FORUM via THORN RUN PARTNERS
2023 · third_quarter · Q3
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023. S.2305 - Biosimilar Red Tape Elimination Act.
Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE BIOSIMILARS FORUM via THORN RUN PARTNERS
2023 · second_quarter · Q2
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Seniors Act. S.4302 - Senator Marshall, the Biologics Market Transparency Act. H.R.2679 - Pharmacy Benefits Manager Accountability Act. H.R.1790 - Biologics Competition Act of 2023.
Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE BIOSIMILARS FORUM via THORN RUN PARTNERS
2023 · first_quarter · Q1
Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE BIOSIMILARS FORUM via THORN RUN PARTNERS
2022 · fourth_quarter · Q4
Drug pricing legislation. H.R.4502 - Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022. H.R.2815 - BIOSIM Act. H.R.2855 - Star Rating for Biosimilars Act. H.R.2869/S.1427 - Increasing Access to Biosimilars Act of 2021. H.R.5376 - Inflation Reduction Act of 2022. Efforts surrounding user fees. H.R.7006 - INSPECTIONS Act.
Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. H.R.2617 - Consolidated Appropriations Act, 2023, as it relates to the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023. H.R.2815 - BIOSIM Act. H.R.2855 - Star Rating for Biosimilars Act. H.R.2869/S.1427 - Increasing Access to Biosimilars Act of 2021. H.R.5376 - Inflation Reduction Act of 2022
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE